Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On Track" to Initiate Phase 1 First-in-human Clinical Trials Mid-2024
Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On Track" to Initiate Phase 1 First-in-human Clinical Trials Mid-2024
由于支出增加，Satellos Bioscience第一季度亏损扩大；但表示 “步入正轨”，将在2024年中期启动第一阶段首次人体临床试验
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册